Semaglutide and Diabetic Retinopathy: The Paradoxical Worsening in Early Treatment

Written by Adam Maggio | Medically reviewed by Dr. James Whitfield, DO, FACOI

Semaglutide, while beneficial for diabetes, can paradoxically worsen diabetic retinopathy in early treatment due to rapid glycemic control, necessitating careful monitoring and ophthalmological assessment for at-risk patients.

Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), has revolutionized the management of type 2 diabetes and obesity due to its potent glucose-lowering and weight-reducing effects. However, early clinical trials, particularly the SUSTAIN-6 trial, raised concerns about a paradoxical worsening of diabetic retinopathy (DR) in some patients initiating semaglutide therapy [1]. This phenomenon, while seemingly counterintuitive given the overall benefits of glycemic control, warrants careful consideration and understanding.

The Paradoxical Worsening: Clinical Observations

The SUSTAIN-6 trial, a cardiovascular outcomes trial for semaglutide, observed a higher rate of DR complications in the semaglutide group compared to placebo, particularly in patients with pre-existing retinopathy at baseline [1]. Specifically, a composite outcome of retinopathy events (e.g., vitreous hemorrhage, retinal detachment, or blindness) occurred in 3.0% of patients receiving semaglutide versus 1.8% in the placebo group (Hazard Ratio 1.76; 95% CI, 1.11 to 2.78; P=0.02) [1].

This early worsening is not unique to semaglutide or GLP-1 RAs; it has also been observed with other intensive glucose-lowering interventions, including insulin therapy, particularly in patients with long-standing diabetes and poorly controlled hyperglycemia [2]. The key characteristic is the rapidity of glycemic improvement.

Proposed Mechanisms for Early Worsening

The exact mechanisms underlying this paradoxical worsening are not fully elucidated but are thought to involve several factors related to rapid metabolic shifts:

Rapid Glycemic Normalization: A sudden and significant drop in blood glucose levels can lead to changes in retinal blood flow and oxygenation. The retina, accustomed to a hyperglycemic environment, may experience transient hypoxia and increased oxidative stress as it adapts to normoglycemia. This can exacerbate pre-existing microvascular damage [3].

Autoregulation Dysfunction: In chronic hyperglycemia, retinal blood vessels lose their ability to autoregulate blood flow effectively. Rapid glucose reduction may overwhelm these impaired autoregulatory mechanisms, leading to temporary ischemia and increased vascular permeability [3].

Inflammatory Response: The rapid metabolic changes might trigger an inflammatory response within the retina, contributing to the breakdown of the blood-retinal barrier and worsening of DR [4].

Insulin-like Growth Factor 1 (IGF-1) Changes: Some theories suggest that rapid improvements in glycemic control might lead to transient increases in IGF-1 levels, which can promote retinal neovascularization and exacerbate DR [5].

It is crucial to note that this early worsening is typically transient, often resolving or stabilizing within 12 to 18 months, and does not negate the long-term benefits of sustained glycemic control in preventing DR progression [6].

Clinical Implications and Management Strategies

For clinicians prescribing semaglutide or other GLP-1 RAs, particularly to patients with type 2 diabetes, several considerations are paramount:

Baseline Retinopathy Screening: A comprehensive ophthalmological examination to assess the presence and severity of DR is essential before initiating GLP-1 RA therapy, especially in patients with long-standing diabetes or poor glycemic control [7].

Gradual Glycemic Control: While GLP-1 RAs are highly effective, a more gradual approach to glycemic control might be considered in patients at high risk for DR progression, although this needs to be balanced against the benefits of rapid glucose reduction [7].

Close Ophthalmological Monitoring: Patients with pre-existing DR who initiate semaglutide should undergo more frequent ophthalmological monitoring, particularly during the initial months of treatment, to detect and manage any worsening promptly [7].

Patient Education: Patients should be informed about the potential for transient worsening of DR and the importance of continued ophthalmological follow-up. Reassurance about the long-term benefits of glycemic control is also vital.

Long-Term Perspective

Despite the initial concerns, subsequent analyses and real-world data suggest that the overall long-term effect of GLP-1 RAs on DR is either neutral or beneficial, primarily due to their sustained positive impact on glycemic control, weight, and cardiovascular risk factors [8]. The paradoxical early worsening is a complex phenomenon that highlights the delicate balance of metabolic regulation in DR. By understanding these nuances and implementing appropriate monitoring strategies, clinicians can optimize the benefits of semaglutide while mitigating potential risks.